Bull&Bear | Digital Turbine and Harrow Lead Gains, Cardlytics and BRC See Sharp Declines
Thursday, Aug 8, 2024 6:00 pm ET
Bull Stocks:
Digital Turbine (APPS) surged by 61.80%, marking a continuous two-day rise, with a total increase of 61.80% over the past two days. The company's first-quarter performance exceeded expectations, and it anticipates sustained demand growth in the latter half of fiscal 2025.
Harrow (HROW) rose by 54.32%. Harrow's strong performance in the second quarter of 2024 drove its stock price higher. The transcript of the earnings call revealed significant advancements in various key areas, including revenue growth and cost control, boosting market confidence in the company’s future performance.
XPEL (XPEL) increased by 47.69%. Craig-Hallum upgraded Xpel's rating from Hold to Buy.
SkyWater Technology (SKYT) climbed by 47.55%. SkyWater Technology's robust Q2 performance and improved profitability led to a buy rating.
Emergent BioSolutions (EBS) rose by 46.85%. Despite Emergent BioSolutions reporting a larger-than-expected loss for the second quarter, its stock price saw an uptick.
Bear Stocks:
Cardlytics (CDLX) plummeted by 57.10%, experiencing a two-day decline, with a total drop of 59.56% over the past two days. The decline followed the company's announcement of worse-than-expected Q2 financial results and a lower-than-anticipated forecast for Q3 revenue.
BRC (BRCC) fell by 37.82%. The company's stock price dropped after it reported Q2 revenue results that fell short of expectations.
Cabaletta Bio (CABA) decreased by 34.37%, marking a two-day decline, with a total drop of 38.59% over the past two days. The stock's decline was triggered by the company's Q2 financial performance.
Ironwood Pharmaceuticals (IRWD) dropped by 32.61%, continuing a seven-day losing streak, with a total decline of 41.64% over the past seven days. The company's non-GAAP earnings per share were reported at $0.00, missing expectations by $0.14, with revenue coming in at $94.4 million, falling short by $12.6 million.
FEBO (FEBO) fell by 29.51%. While top executive Lee Jiensheng, the most optimistic insider, increased their holdings by 44% last week, the stock still saw a significant decline.
Digital Turbine (APPS) surged by 61.80%, marking a continuous two-day rise, with a total increase of 61.80% over the past two days. The company's first-quarter performance exceeded expectations, and it anticipates sustained demand growth in the latter half of fiscal 2025.
Harrow (HROW) rose by 54.32%. Harrow's strong performance in the second quarter of 2024 drove its stock price higher. The transcript of the earnings call revealed significant advancements in various key areas, including revenue growth and cost control, boosting market confidence in the company’s future performance.
XPEL (XPEL) increased by 47.69%. Craig-Hallum upgraded Xpel's rating from Hold to Buy.
SkyWater Technology (SKYT) climbed by 47.55%. SkyWater Technology's robust Q2 performance and improved profitability led to a buy rating.
Emergent BioSolutions (EBS) rose by 46.85%. Despite Emergent BioSolutions reporting a larger-than-expected loss for the second quarter, its stock price saw an uptick.
Bear Stocks:
Cardlytics (CDLX) plummeted by 57.10%, experiencing a two-day decline, with a total drop of 59.56% over the past two days. The decline followed the company's announcement of worse-than-expected Q2 financial results and a lower-than-anticipated forecast for Q3 revenue.
BRC (BRCC) fell by 37.82%. The company's stock price dropped after it reported Q2 revenue results that fell short of expectations.
Cabaletta Bio (CABA) decreased by 34.37%, marking a two-day decline, with a total drop of 38.59% over the past two days. The stock's decline was triggered by the company's Q2 financial performance.
Ironwood Pharmaceuticals (IRWD) dropped by 32.61%, continuing a seven-day losing streak, with a total decline of 41.64% over the past seven days. The company's non-GAAP earnings per share were reported at $0.00, missing expectations by $0.14, with revenue coming in at $94.4 million, falling short by $12.6 million.
FEBO (FEBO) fell by 29.51%. While top executive Lee Jiensheng, the most optimistic insider, increased their holdings by 44% last week, the stock still saw a significant decline.